Finance

Results: 13465-13476 of 49484

4Moving Biotech (4MB), a clinical stage biotechnology company developing next-generation, disease-modifying therapies for osteoarthritis (OA), today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for 4P004, enabling the expansion of the Phase 2a INFLAM MOTION clinical trial into the United States (US).

4Moving Biotech Receives FDA IND Clearance for 4P004, Strengthening Its Position as a Leading Innovator in Disease-Modifying Osteoarthritis Therapeutics

Organon Enters into a Commercialization Agreement for Daiichi Sankyo’s Nilemdo® in France, Denmark, Iceland, Sweden, Finland and Norway

PR Newswire associated0

CHAGEE Releases "2025 Year-End Tea Friends Review": Global Stores Span 8 Countries Across 2 Continents, Annual Tea Procurement Exceeds 10,000 Tons

CHiQ Named One of the '2025-2026 Global Smart Home Brands Top 10' at CES

Invitation to presentation of EQT AB's Year-end Report 2025

Azafaros to Present at J.P. Morgan’s 44th Annual Healthcare Conference

"STRIKE WORLD: Deadverse Reloaded the Anime" Available on Prime Video Worldwide from January 7, 2026

PR Newswire associated0

Hyundai Mobis Forms Strategic Collaboration Framework with Boston Dynamics!

PR Newswire associated0

Courtyard by Marriott Phuket, Patong Beach Resort: The Ultimate Family-Friendly Destination in 2026

Zilch to Acquire Fjord Bank to Kickstart European Expansion

Zilch to Acquire Fjord Bank to Kickstart European Expansion

Dr. Anand Tharmaratnam, Novotech CEO and Chairman

Novotech Appoints Anand Tharmaratnam as New CEO

RE Royalties Announces up to a USD $9.0 Million Portfolio-Level Royalty Investment with Solaris Energy Inc.